Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure

American Journal of Cardiology

Volumn 92, Issue 4, 2003, Pages 406-410

  Fung, Jeffrey W H ^a   Yu, Cheuk M ^b   Yip, Gabriel ^b   Chan, Skiva ^b   Yandle, Timothy G ^b   Richards, A Mark ^b   Nicholls, M Gary ^b   Sanderson, John E ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ATRIAL NATRIURETIC FACTOR; CARVEDILOL; METOPROLOL; RENIN;

ADD ON THERAPY; ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CARDIOVASCULAR RESPONSE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG EFFECT; DYSPNEA; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; INTERMETHOD COMPARISON; ORGANIC IMPOTENCE; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VERTIGO;

EID: 0041562650     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(03)00658-1     Document Type: Article

References (25)

1. Juillerat L., Nussberger J., Menard J., Mooser V., Christen Y., Waeber B., Graf P., Brunner H.R. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension. 16:1990;564-572.
2. Urata H., Healy B., Stewart R.W., Bumpus F.M., Husain A. Angiotensin-II-forming pathways in normal and failing human hearts. Circ Res. 66:1990;883-890.
3. Struthers A. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail. 2:1996;47-54.
4. Holmer S.R., Hense H.W., Danser A.H., Mayer B., Riegger G.A., Schunkert H. β adrenergic blockers lower renin in patients with ACE inhibitors and diuretics. Heart. 80:1998;45-48.
5. Holmer S.R., Hengstenberg C., Mayer B., Engel S., Lowel H., Riegger G.A., Schunkert H. Marked suppression of renin levels by β-receptor blocker in patients treated with standard heart failure therapy a potential mechanism of benefit from β-blockade . J Intern Med. 249:2001;167-172.
6. Colucci W.S., Elkayam U., Horton D.P. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 343:2000;246-253.
7. Chen H.H., Burnett J.C. Jr. The natriuretic peptides in heart failure diagnostic and therapeutic potentials . Proc Assoc Am Physicians. 111:1999;406-416.
8. Richards A.M., Doughty R., Nicholls M.G., MacMahon S., Sharpe N., Murphy J., Espiner E.A., Frampton C., Yandle T.G. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin prognostic utility and prediction of benefit from carvedilol in chronic ischaemic left ventricular dysfunction . J Am Coll Cardiol. 37:2001;1781-1787.
9. Stanek B., Frey B., Hulsmann M., Berger R., Sturm B., Strametz-Juranek J., Bergler-Klein J., Moser P., Bojic A., Hartter E., Pacher R. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advance left ventricular dysfunction. J Am Coll Cardiol. 38:2001;36-42.
10. Latini R., Masson S., Anand I., Judd D., Maggioni A.P., Chiang Y.T., Bevilacqua M., Salio M., Cardano P., Dunselman P.H., et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure the Valsartan Heart Failure Trial (Val-HeFT) . Circulation. 106:2002;2454-2458.
11. Sanderson J.E., Chan S.K., Yip G., Yeung L.Y., Chan K.W., Raymond K., Woo K.S. Beta-blockade in heart failure a comparison of carvedilol with metoprolol . J Am Coll Cardiol. 34:1999;1522-1528.
12. Nussberger J., Fasanella d'Amore T., Porchet M., Waeber B., Brunner D.B., Brunner H.R., Kler L., Brown A.N., Francis R.J. Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers. J Cardiovasc Pharmacol. 9:1987;39-44.
13. Lun S., Espiner E.A., Nicholls M.G., Yandle T.G. A direct radioimmunoassay for aldosterone in plasma. Clin Chem. 29:1983;268-271.
14. Hunt P.J., Richards A.M., Nicholls M.G., Yandle T.G., Doughty R.N., Espiner E.A. Immunoreactive aminoterminal pro-brain natriuretic peptide (NT-PROBNP) a new marker of cardiac impairment . Clin Endocrinol. 47:1997;287-296.
15. Florkowski C.M., Richards A.M., Espiner E.A., Yandle T.G., Frampton C. Renal, endocrine, and hemodynamic interactions of atrial and brain natriuretic peptides in normal men. Am J Physiol. 266:1994;R1244-R1250.
16. Lainchbury J.G., Troughton R.W., Lewis L.K., Yandle T.G., Richards A.M., Nicholls M.G. Hemodynamic, hormonal, and renal effects of short term adrenomedullin infusion in healthy volunteers. J Clin Endocrinol Metab. 85:2000;1016-1020.
17. Schunkert H., Hense H.W., Brockel U., Luchner A., Muscholl M., Holmer S.R., Danser A.H., Mayer B., Riegger G.A. Differential effects of antihypertensive drugs on neurohormonal activation insights from a population-based sample . J Intern Med. 244:1998;109-119.
18. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy the randomized evaluation of strategies for left ventricular dysfunction pilot study . Circulation. 101:2000;378-384.
19. Massie B.M. Neurohumoral blockade in chronic heart failure how much is enough? Can there be too much? J Am Coll Cardiol. 39:2002;79-82.
20. Troughton R.W., Frampton C.M., Yandle T.G., Espiner E.A., Nicholls M.G., Richards A.M. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 355:2000;1126-1130.
21. Packer M., Bristow M.R., Cohn J.N., Colucci W.S., Fowler M.B., Gilbert E.M., Shusterman N.H. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 334:1996;1349-1355.
22. Effect of metoprolol CR/XL in chronic heart failure Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) . Lancet. 353:1999;2001-2007.
23. Packer M., Coats A.J., Fowler M.B., Katus H.A., Krum H., Mohacsi P., Rouleau J.L., Tendera M., Castaigne A., Roecker E.B., Schultz M.K., DeMets D.L. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 344:2001;1651-1658.
24. Sandberg A., Blomquist I., Jonssn U.E., Lundborg O. Pharmacokinetic and pharmacodynamic properties of a new controlled-release formulation of metoprolol a comparison with conventional tablets . Eur J Clin Pharmacol. 33:(suppl):1988;S9-S14.
25. Wikstrand J., Hjalmarson A., Waagstein F., Fagerberg B., Goldstein S., Kjekshus J., Wedel H. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure analysis of the experience in Metoprolol CR/XL Randomized Intervention Trial in chronic Heart Failure (MERIT-HF) . J Am Coll Cardiol. 40:2002;491-498.